Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 10/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | HPGDS | O60760 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29167802 | 1.00 | NAMPT (0.61) | NAMPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL13868569 | 1.00 | NAMPT (0.61) | NAMPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL364174 | 0.90 | NPC1 (0.62) | NAMPTNPC1RAB9AMEN1KMT2A | |
| Water SCHEMBL30838095 | 0.88 | NPC1 (0.60) | NAMPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL12505662 | 0.86 | NPC1 (0.56) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL14797411 | 0.84 | NAMPT (0.52) | NAMPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL27962735 | 0.83 | KDM1A (0.54) | NAMPTNPC1RAB9AKDM1AHPGDS | |
| SCHEMBL30968148 | 0.83 | ALDH1A1 (0.52) | NAMPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL30968047 | 0.83 | ALDH1A1 (0.52) | NAMPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL23387883 | 0.82 | ALDH1A1 (0.59) | NAMPTRAB9ASMN1; SMN2HPGDSALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117647598-A | High performance liquid analysis method for enantiomer of (S) -3-amino tetrahydrofuran and intermediate | 上海司太立制药有限公司 | 2024-03-05 | — | — | CN | claimed |
| EP-1126843-A4 | COMPOUNDS DERIVED FROM AN AMINE NUCLEUS THAT ARE INHIBITORS OF IMPDH ENZYME | BRISTOL MYERS SQUIBB CO (US) | 2005-06-15 | — | — | EP | claimed |
| EP-1126843-A1 | COMPOUNDS DERIVED FROM AN AMINE NUCLEUS THAT ARE INHIBITORS OF IMPDH ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-29 | — | — | EP | claimed |
| WO-2000025780-A1 | COMPOUNDS DERIVED FROM AN AMINE NUCLEUS THAT ARE INHIBITORS OF IMPDH ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-05-11 | — | — | WO | claimed |
| EP-4630410-A1 | POLQ INHIBITORS | Astrazeneca AB (SE) | 2025-10-15 | — | — | EP | disclosed |
| CN-113382730-B | Selective glucocorticoid receptor modifier for use in the treatment of impaired skin wound healing | 阿克里斯生物医药有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-115697993-B | Pyrimidine compounds as AXL inhibitors | 南京正大天晴制药有限公司 | 2024-12-10 | — | — | CN | disclosed |
| WO-2024121753-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-13 | — | — | WO | disclosed |
| CN-117647598-A | High performance liquid analysis method for enantiomer of (S) -3-amino tetrahydrofuran and intermediate | 上海司太立制药有限公司 | 2024-03-05 | — | — | CN | disclosed |
| CN-116710433-A | Selective PARP1 inhibitor and application thereof | 成都百裕制药股份有限公司 | 2023-09-05 | — | — | CN | disclosed |
| US-20230227484-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| CN-111655700-B | Oxadiazolopyridine derivatives as ghrelin O-acyltransferase (GOAT) inhibitors | 勃林格殷格翰国际有限公司 | 2023-07-18 | — | — | CN | disclosed |
| WO-2019238067-A1 | PYRROLO [2, 3-B] PYRIDINES OR PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2019-12-19 | — | — | WO | disclosed |
| EP-3568390-A1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2019-11-20 | — | — | EP | disclosed |
| US-10421734-B1 | Process for the preparation of enantiopure 3-amino tetrahydrofuran and its salts | SAMI LABS LIMITED (IN) | 2019-09-24 | — | — | US | disclosed |
| WO-2018132372-A1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2018-07-19 | — | — | WO | disclosed |
| EP-2419423-A1 | FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS | Cellzome Limited (GB) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010118986-A1 | FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS | CELLZOME LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
| US-7514573-B2 | Processes for the manufacture of chiral and racemic forms of 3-aminotetrahydrofurans, their salts and derivatives | SAMI LABS LTD (IN) | 2009-04-07 | — | — | US | disclosed |
| US-20080255377-A1 | reduction of diesters of aspartic acid, then cyclization with the aid of sulfonic acids, hydrolysis using a base to give 3-(S)-aminotetrahydrofuran as its hydrochloride or p-toluenesulfonate salt, or as base itself | MAJEED MUHAMMED | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255377-A1 | reduction of diesters of aspartic acid, then cyclization with the aid of sulfonic acids, hydrolysis using a base to give 3-(S)-aminotetrahydrofuran as its hydrochloride or p-toluenesulfonate salt, or as base itself | AASDHPPT, DNPEP, ASNS | NAMPT 780/4885NPC1 4777/4885RAB9A 4799/4885 |
| US-20230227484-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | AXL, FLT3, TYMP | NAMPT 43/4885NPC1 4461/4885RAB9A 2614/4885 |
| US-10421734-B1 | Process for the preparation of enantiopure 3-amino tetrahydrofuran and its salts | AASDHPPT, AAAS, AADAT | NAMPT 1017/4885NPC1 4097/4885RAB9A 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.